Fig. 6: REV3L expression is important for cellular resistance to cisplatin in three-dimensional-cultured cells and cancer patients. | Cell Death & Disease

Fig. 6: REV3L expression is important for cellular resistance to cisplatin in three-dimensional-cultured cells and cancer patients.

From: ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation

Fig. 6

a, b REV3L and GAPDH (endogenous control) mRNA expression levels assessment, by quantitative PCR assays, a in MCF-7 cells co-treated with VE-821 (ATR pharmacological inhibitor) and cisplatin for 24 h and b in REV3L-deficient (shREV3L) and scramble control (ctrl) MCF-7 cells. c Cellular viability of shREV3L and ctrl MCF-7 cells’ exposure to VE-821 and cisplatin for 72 h. d–f Analysis of Rev3L mRNA expression correlation with cancer patients’ response to cisplatin, using The Cancer Genome Atlas (TCGA) database. d Number of patients treated with cisplatin by cancer type. Cancer types with >40 cisplatin-treated patients were selected for analysis and are highlighted in red. e, f Kaplan–Meier survival curves of cisplatin-treated patients divided according to the mRNA expression of REV3L in pretreatment biopsies of e cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) and f bladder urothelial carcinoma (BLCA). a–c The results are presented as mean ± SEM from two independent experiments performed in triplicate. a One-way analysis of variance (ANOVA) followed by Tukey post-test, b Student t test, and c two-way ANOVA and Bonferroni post-hoc test were used for statistical analysis and the differences were considered significant for *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001. ns highlights non-significant changes. e, f Comparisons were performed using log-rank test. d Types of cancer presented: CESC, BLCA, head and neck cell carcinoma HPV− (HNSC HPV−), lung adenocarcinoma (LUAD), ovarian serous cystadenocarcinoma (OV), lung squamous cell carcinoma (LUSC), stomach adenocarcinoma (STAD), esophageal carcinoma (ESCA), mesothelioma (MESO), uterine corpus endometrial carcinoma (UCEC), uterine carcinosarcoma (UCS), cholangiocarcinoma (CHOL), glioblastoma multiforme (GBM), head and neck cell carcinoma HPV+ (HNSC HPV+), thymoma (THYM), liver hepatocellular carcinoma (LIHC), sarcoma (SARC), skin cutaneous melanoma (SKCM), pancreatic adenocarcinoma (PAAD)

Back to article page